Share Issue News

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 7,850 shares of the Company’s common stock at an exercise price per share of $22.65, which was the...

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today that it does not intend to exercise its right to redeem all or any part of the currently outstanding Cumulative Minimum Rate Reset First Preferred Shares, Series J of the Company (the “Series J Shares”) on May 15, 2026. There are currently 8,000,000 Series J Shares outstanding. Subject to certain conditions set out in the prospectus supplement of the Company dated March 26, 2021,...

BOSTON--(BUSINESS WIRE)--MFS Municipal Closed-End Funds Announce Completion of Special Shareholder Meetings. Shareholders approved all proposals....

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on April 6, 2026 (the “Grant Date”). The Inducem...

NEW YORK--(BUSINESS WIRE)--Tamboran Resources Corporation (NYSE: TBN, ASX: TBN): Other Information The offering of these securities is being made only by means of the prospectus supplement and accompanying base prospectus as filed with the SEC. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained free of charge on the SEC’s website at www.sec.gov under Tamboran’s name or from the joint book-running managers as follows: RBC Cap...

TORONTO--(BUSINESS WIRE)--Sherritt International Corporation (“Sherritt” or the “Corporation”) (TSX:S) today announced that it has closed its previously announced non-brokered private placement of common shares of Sherritt (“Common Shares”) raising total gross proceeds of approximately $43.5 million (the "Private Placement"). Pursuant to the Private Placement, the Corporation issued approximately 207 million Common Shares from treasury at a price of $0.21 per Common Share. As part of the Privat...

NEW YORK--(BUSINESS WIRE)--Tamboran Resources Corporation (NYSE: TBN, ASX: TBN): Other Information The offering of these securities is being made only by means of the prospectus supplement and accompanying base prospectus as filed with the SEC. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained free of charge on the SEC’s website at www.sec.gov under Tamboran’s name or from the placement agent as follows: RBC Capital Markets...

LIMOGES, France--(BUSINESS WIRE)--Regulatory News: Legrand (Paris:LR): Date Total number of shares composing the share capital Total number of voting rights March 31, 2026 262,245,733 Theoretical number of voting rights: 262,245,733 Number of exercisable voting rights*: 261,364,529 (*) After deduction of shares without voting rights The variation of the total number of shares since the latest release of financial statements is reminded below: Total number of shares as at January 31, 2026 262,24...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock...